Sources | Names Used |
---|---|
CTRPv2 | doxorubicin:navitoclax (2:1 mol/mol) |
PharmacoGx | doxorubicin:navitoclax (2:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | ILK | CTRPv2 | pan-cancer | AAC | -0.14 | 6e-05 |
mRNA | TCEANC2 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
mRNA | SPHK2 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
mRNA | MMP11 | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | EDEM1 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
mRNA | INA | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
mRNA | CYTH4 | CTRPv2 | pan-cancer | AAC | 0.15 | 6e-05 |
mRNA | MAPK8IP1 | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
mRNA | CNTROB | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |
mRNA | ZNF362 | CTRPv2 | pan-cancer | AAC | 0.13 | 6e-05 |